Validation of a Prognostic Method for Assessing the Risk of Distant Metastasis in Early-stage Breast Cancer

Plain-language summary

This study assesses the accuracy of a prognostic method for predicting the risk of distant metastasis (spread to distant parts of the body) in early-stage breast cancer. Patients over 18 with stage I-III breast cancer who have residual tumor tissue available can take part. It is a study without an assigned phase and is enrolling by invitation.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Enrolling by invitation

Sponsor

Casa Sollievo della Sofferenza IRCCS

Intervention

Validation of Prognostic tool

Start date

3/10/2022

Estimated completion

12/31/2026

Countries

Italy

Related genes

Locations

• San Giovanni Rotondo, Italy

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Stage I-III breast cancer
* Residual tumor tissue available
* Written informed consent

Exclusion Criteria:

* Age \<18
* Stage IV at diagnosis
* Refusal or inability to provide informed consent